David Sholehvar - Aug 1, 2022 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Role: President, Clinical Services
Signature: /s/ Ali Olivo, Attorney-in-Fact
Stock symbol: NEO
Transactions as of: Aug 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 8/3/2022, 05:45 PM
Previous filing: Apr 4, 2022
Next filing: Nov 14, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NEO	Common Stock	Award	$0	+12.4K	+40.02%	$0.00	43.2K	Aug 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NEO	Stock Option (Right to Buy)	Award	$0	+25.8K		$0.00	25.8K	Aug 1, 2022	Common Stock	25.8K	$10.12	Direct	F3
holding	NEO	Stock Option (Right to Buy)						66.4K	Aug 1, 2022	Common Stock	66.4K	$12.15	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 1, 2022, Dr. Sholehvar was granted 12,352 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.
F2	On April 1, 2022, Dr. Sholehvar was granted 66,372 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F3	On August 1, 2022, Dr. Sholehvar was granted 25,826 stock options. These options vest ratably over the first four anniversary dates of the grant date.